[{"id":"6597b7e7-80e5-4a8e-9881-9c013dcb4c2e","acronym":"AHEAD-MERIT","url":"https://clinicaltrials.gov/study/NCT04534205","created_at":"2021-01-18T21:42:20.218Z","updated_at":"2025-02-25T16:26:00.326Z","phase":"Phase 2","brief_title":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","source_id_and_acronym":"NCT04534205 - AHEAD-MERIT","lead_sponsor":"BioNTech SE","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • BNT113"],"overall_status":"Recruiting","enrollment":" Enrollment 285","initiation":"Initiation: 01/07/2021","start_date":" 01/07/2021","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-01-28"}]